- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Eleanor Perfetto, PhD, MS, Discusses How HEOR Departments Use Comparative Effectiveness Research
Comparative effectiveness research (CER) collaborative tools can benefit pharmaceutical companies in a variety of ways.
Comparative effectiveness research (CER) collaborative tools can benefit pharmaceutical companies in a variety of ways. Eleanor Perfetto, PhD, MS, professor, pharmaceutical health services research, School of Pharmacy, University of Maryland, for instance, suggests that CER can be utilized in internal training programs as well as in making research studies translatable to managed care organizations and their leaders.
“For the most part, the responsibilities within the company are to get a drug approved, and that relies heavily on a randomized control trial design. Now that we have decision-makers who are out there looking at aspects beyond what the FDA would be looking for when a drug is being approved, they’re looking for some of the endpoints the FDA would consider secondary,” says Dr Perfetto.
She adds that the role of HEOR groups within pharmaceutical organizations will continue to grow and evolve.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
